Exchange: NASDAQ·Updated 03:08 PM EDT

ROIV News

News
all
press releases
Here's How Much You Would Have Made Owning Roivant Sciences Stock In The Last 5 Years
Roivant Sciences (NASDAQ:ROIV) has outperformed the market over the past 5 years by 30.08% on an annualized basis producing an average annual return of 41.86%. Currently, Roivant Sciences has a market capitalization ofread more...
Benzinga
Here's How Much You Would Have Made Owning Roivant Sciences Stock In The Last 5 Years
Roivant Sciences (NASDAQ:ROIV) has outperformed the market over the past 5 years by 30.08% on an annualized basis producing an average annual return of 41.86%. Currently, Roivant Sciences has a market capitalization ofread more...
Benzinga
More News
IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class
Immunovant is developing IMVT-1402 in an ongoing mid-stage study in Sjögren’s disease, which works the same way as Argenx’s efgartigimod.
Stocktwits
Here's How Much You Would Have Made Owning Roivant Sciences Stock In The Last 5 Years
Roivant Sciences (NASDAQ:ROIV) has outperformed the market over the past 5 years by 27.07% on an annualized basis producing an average annual return of 39.09%. Currently, Roivant Sciences has a market capitalization ofread more...
Benzinga
Why Did DELL, ROIV, SHEL Stocks Surge To 52-Week Highs Today?
Investors rewarded three very different catalysts spanning artificial intelligence, biotechnology, and energy.
Stocktwits
Stocks Making Noise as the Market Hunts for Its Next Big Winners
The small-cap market is serving up a mix of stories centered on PDS Biotech (NASDAQ:PDSB), NeOnc (NASDAQ:NTHI), CEA Industries (NASDAQ:BNC), Bluejay Diagnostics (NASDAQ:BJDX), NuRAN Wireless (NASDAQ:NUR) and Roivant Sciences (NASDAQ:ROIV).
24-7 Market News
These 2 Biotech Stocks Hit Record Highs Today – What’s Driving The Rallies?
Roivant Sciences reported positive Phase 2 results for its experimental lung disease drug, Mosliciguat, while Pharvaris’ oral therapy met the main goal of a Phase 3 study of preventive treatment for hereditary angioedema.
Stocktwits
Roivant Sciences, Pharvaris, IonQ And Other Big Stocks Moving Higher On Tuesday
U.S. stocks fell Tuesday, but Roivant surged 16% on positive PH-ILD trial data. Pharvaris, Solaris, IonQ and quantum stocks also posted strong gains.read more...
Benzinga
Roivant’s Experimental Lung Disease Drug Hits Key Phase 2 Goal – ROIV Stock Tracks All-Time High
Roivant’s Mosliciguat reduced pulmonary vascular resistance by 56.3% compared with placebo after 16 weeks.
Stocktwits
ABUS Stock Surges 10% Today — What’s Driving This Super Rally?
Arbutus Biopharma said it will repurchase $230 million of its common shares at a purchase price of not less than $5 per share and not more than $5.75 apiece, in cash.
Stocktwits
Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of 0.00% and -35.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.